Table 3 Comparison of telbivudine and lamivudine in patients with chronic hepatitis B.

	HBeAg negative
	Telbivudine	Lamivudine	p Value
52 weeks
PCR negative (%)	88	71	<0.01
HBeAg loss (%)
HBeAg seroconversion (%)
Resistance	2	7	<0.01
Primary treatment failure (%)	0	3
76 weeks
PCR negative (%)	84	67	<0.05
HBeAg seroconversion (%)

HBeAg, hepatitis B e antigen; PCR, polymerase chain reaction.